Difficult clinical decisions in gynecological oncology: identifying priorities for future clinical research. Issue 1 (1st January 2006)

• Record Type: Journal Article
• Authors: Harrison, J. D.; Carter, J.; Young, J. M.; Solomon, M. J.
• Is Part Of: International journal of gynecological cancer. Volume 16:Issue 1(2006)
• Page Start: 1
• Page End: 7
• Publication Date: 2006-01-01
• Subjects: feasibility -- gynecologic oncology -- randomized controlled trials (RCTs); Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-00009577-200601000-00001
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : This study investigates the acceptability and feasibility of conducting randomized controlled trials (RCTs) in gynecological oncology by ascertaining the views of the Australian Society of Gynaecologic Oncologists (ASGO) about important clinical questions in this field, current treatment preferences, and willingness to participate in trials to address these questions. Members of ASGO received a mailed survey. Thirty-one gyneoncologists participated in this study (79% response fraction). There was considerable support for an RCT (81%; 95% confidence interval [CI], 63–93%) to compare sentinel node biopsy with total groin dissection for women with vulval cancer. This clinical question was also rated as "extremely" or "very" important by 91% (95% CI, 74–98%) of respondents, who also indicated high levels of individual equipoise. Another priority for research involved the use of second-line chemotherapy for women who have rising CA125 titers. This clinical question was rated as extremely or very important by 71% (95% CI, 52–86%), exhibited high levels of individual equipoise, with 74% (95% CI, 55–88%) of respondents willing to participate in an RCT to address this issue. The conduct of surveys of representative groups of clinicians provides useful empirical data to focus clinical research efforts where they are most likely to be successful based on equipoise, feasibility, and clinical interest.